|
Interface Biologics, Inc. |
|
|
101 College Street, Suite 300
Toronto, Ontario M5G 1L7 Canada
phone:(1) 416 673 8170
fax:(1) 416 977 1329
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
18 |
|
|
| www.interfacebiologics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Biomedical polymer technology for thrombosis and drug delivery |
|
| Management |
| Tom P. Reeves, President & C.E.O.; Dr. Peng Chen, Ph.D., Quality Assurance Manager/ Analytical Lab Manager; Kevin Palmer, Vice President, Finance; Roseita Esfand, Ph. D., Director, Research & Development; Jeannette Ho, Director of Operations; Sanjoy Mullick, Ph. D., Senior Scientist; Paul Santerre, Ph.D., Chief Scientific Officer; Mark Steedman, Vice President, Business Development |
| |
|
|
| |
|
| Keywords |
| biomaterials, combination drug delivery devices, cardiovascular, urogenital, implant, vascular access, hollow fiber membranes, dialyzers |
|
|
|
| Description |
|
Interface Biologics, Inc. develops biomedical polymer technology to improve the safety and effectiveness of medical devices, especially those that reduce thrombosis without using heparin. Thrombosis costs the US $1B annually, and contemporary methods of treatment for thrombosis involve devices that are either uncoated or coated with heparin or other lubricous materials; these coatings have limited long-term effectiveness, and heparin is contra-indicated in many patients. Interface has developed Endexo anti-thrombogenic additives, which are low-molecular-weight fluoro-oligomers that impart a passivating surface to the implantable medical devices, thereby reducing platelet adhesion and thrombus formation. These additives have fluorinated end groups that bloom to the top 10 nanometers of the device surface during device manufacturing, and are compatible with a wide range of base polymers and manufacturing processes, withstanding processing temperatures of up to 310°F; moreover, because they are additives rather than coatings, they render minimal impact on the physical and performance features of the original device. Additionally, Interface’s Epidel solution is aimed to combat infections resultant from implantable medical devices, which current state-of-the-art in infection control addresses with some form of silver-containing coating with limited duration. |
|
| Technology / Differentiation |
Endexo: Self-locating fluoro-ologomeric additives that result in a passivating surface that reduces platelet adhesion and thrombosis.
Epidel: Long chain polymers that release pharmaceuticals to fight infection.
Kinesyx: Surface pacifying oligomers that incorporate pharmaceuticals or biologics for transient or sustained drug release. |
|
| Market / Customers |
Major medical device manufacturers
|
|
| Status |
| Early commercial stage: 3 OEM licensing agreements signed
Expect to have FDA approved products on the market in early 2012 |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members